Related Experiment Video
Updated: Jul 8, 2026
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Secondary B-Cell Acute Lymphoblastic Leukemia Following Multiple Myeloma Treatment
Clinical Laboratory
|July 7, 2026
Abstract
Background:
Secondary B-cell acute lymphoblastic leukemia (B-ALL) following multiple myeloma (MM) is rare.
Methods And Results:
Our case presents a patient with non-secretory MM, using bortezomib-based induction, autologous transplantation, and sequential Lenalidomide maintenance treatment and persistent complete remission (CR) for about 5 years. Then the patient got secondary B-ALL.
Conclusions:
Autologous stem cell transplant with bortezomib therapy has achieved CR of patients with MM, but also has an increased risk of secondary B-ALL.
